financetom
Business
financetom
/
Business
/
UBS to Launch $2 Billion Share Repurchase Program
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UBS to Launch $2 Billion Share Repurchase Program
Apr 2, 2024 3:06 AM

05:41 AM EDT, 04/02/2024 (MT Newswires) -- UBS (UBS) said Tuesday it is planning to launch a stock repurchase program for up to $2 billion of its shares beginning on Wednesday and ending on April 2, 2026.

Based on UBS's March 27 closing price, the repurchase program encompasses about 64.1 million shares or about 1.85% of outstanding shares.

The share repurchase will be conducted via a trading line on the SIX Swiss Exchange. The shares will be repurchased for a capital reduction, the company said.

A repurchase program launched in 2022 ended March 28 after buying back 5.01 billion Swiss francs ($5.24 billion) worth of shares.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Super Hi International Q3 Earnings Fall, Revenue Rises
Super Hi International Q3 Earnings Fall, Revenue Rises
Nov 26, 2025
05:26 AM EST, 11/26/2025 (MT Newswires) -- Super Hi International ( HDL ) reported Q3 earnings Wednesday of $0.01 per diluted share, down from $0.06 a year earlier. Revenue for the quarter ended Sept. 30 was $214 million, up from $198.6 million a year earlier. Two analysts surveyed by FactSet expected $228.4 million. ...
Ascendis Pharma Says FDA Extended Review Period for TransCon CNP in Children With Achondroplasia by Three Months
Ascendis Pharma Says FDA Extended Review Period for TransCon CNP in Children With Achondroplasia by Three Months
Nov 26, 2025
05:27 AM EST, 11/26/2025 (MT Newswires) -- Ascendis Pharma ( ASND ) said late Tuesday that the US Food & Drug Administration has extended the review period for its TransCon CNP drug candidate to treat children with achondroplasia, which causes dwarfism, by three months to Feb. 28, 2026. The FDA notified the company that its submission related to post-marketing requirements...
Pinnacle Financial Partners, Synovus Financial Secure US Federal Reserve Approval for Planned Merger
Pinnacle Financial Partners, Synovus Financial Secure US Federal Reserve Approval for Planned Merger
Nov 26, 2025
05:42 AM EST, 11/26/2025 (MT Newswires) -- Pinnacle Financial Partners ( PNFP ) and Synovus Financial ( SNV ) said late Tuesday their planned merger received regulatory approval from the US Federal Reserve. Shareholders of both companies already approved the merger on Nov. 6 and the transaction is now expected to close on Jan. 1, 2026, the companies said. The...
Update: Nutanix Fiscal Q1 Adjusted EPS In-Line But Revenue Misses; Cuts Full-Year Sales Outlook; Shares Sink Premarket
Update: Nutanix Fiscal Q1 Adjusted EPS In-Line But Revenue Misses; Cuts Full-Year Sales Outlook; Shares Sink Premarket
Nov 26, 2025
05:30 AM EST, 11/26/2025 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Nutanix ( NTNX ) shares were down more than 16% in Wednesday's premarket activity after the company reported overnight Q1 sales growth that lagged market expectations, and the outlook for full-year revenue was also scaled back, taking the shine off in-line...
Copyright 2023-2026 - www.financetom.com All Rights Reserved